Source: International Congress 2018 – Consequences of idiopathic interstitial pneumonias
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
V. Tzilas (Athens, Greece), A. Tzouvelekis (Athens, Greece), E. Bouros (Athens, Greece), T. Karampitsakos (Athens, Greece), S. Kourtidou (Athens, Greece), I. Barbayianni (Athens, Greece), I. Ninou (Athens, Greece), V. Aidinis (Athens, Greece), D. Bouros (Athens, Greece). Vitamin D predicts disease progression in patients with pulmonary fibrosis and blunts in-vitro fibrotic responses. 2902

Member's Comments

No comment yet.

Related content which might interest you: Endotrophin is related to disease progression in idiopathic pulmonary fibrosis Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 Vitamin D status, bone health and hypoxia in patients with advanced pulmonary disease Source: Eur Respir J 2006; 28: Suppl. 50, 65s Year: 2006 Longitudinal serological assessment of neutrophil activity is related to disease progression in idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021 Rate of progression of lung function impairment in α1-antitrypsin deficiency Source: Eur Respir J 2009; 33: 1338-1344 Year: 2009 Treg alterations lead to systemic and local immune deregulation in idiopathic pulmonary fibrosis and collagen vascular disease-associated interstitial pneumonia Source: Annual Congress 2007 - Cell biology of asthma and COPD Year: 2007 17(R)-resolvinD1 improves MMP-9/TIMP-1 imbalance leading to amelioration of pulmonary fibrosis in mice Source: International Congress 2016 – ILD pathogenesis Year: 2016 Markers of pulmonary vascular compromise predict survival in interstitial lung disease (ILD) Source: Annual Congress 2008 - Clinical aspects of interstitial lung disease Year: 2008 Contribution of inflammation and impaired angiogenesis to the pathobiology of chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2015; 46: 431-443 Year: 2015 Exercise pulmonary haemodynamic response predicts outcomes in fibrotic lung disease Source: Eur Respir J, 52 (3) 1801015; 10.1183/13993003.01015-2018 Year: 2018 Relationship between circulating thrombomodulin levels and latent progression of atherosclerosis in patients with chronic obstructive pulmonary disease Source: Annual Congress 2008 - Pulmonary vascular disease and other pulmonary conditions: miscellaneous Year: 2008 Serum surfactant protein D may predict the effect of pirfenidone in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Suppressed pulmonary expression of leptin in lipopolysaccharide-induced acute and chronic lung inflammation Source: Annual Congress 2006 - Novel pathogenic aspects of acute lung injury and acute respiratory distress syndrome (ARDS) Year: 2006 Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone Source: International Congress 2017 – IPF: from the bench to the bedside Year: 2017 Bacterial burden in the lower airways predicts disease progression in idiopathic pulmonary fibrosis and is independent of radiological disease extent Source: Eur Respir J, 55 (4) 1901519; 10.1183/13993003.01519-2019 Year: 2020 Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis Source: Eur Respir Rev, 28 (153) 190022; 10.1183/16000617.0022-2019 Year: 2019 Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020 Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension Source: Eur Respir J, 55 (6) 2000041; 10.1183/13993003.00041-2020 Year: 2020 The cumulative effect of inflammation and infection on structural lung disease in early cystic fibrosis Source: Eur Respir J, 54 (1) 1801771; 10.1183/13993003.01771-2018 Year: 2019 Increasing oxidative stress and inflammation in patients with exacerbated chronic obstructive pulmonary disease (COPD) and their association with lung function Source: Annual Congress 2012 - The smoking gun in COPD biology Year: 2012 Antifibrotics modulate B lymphocyte activation resulting in a decrease of the profibrotic milieu in patients with pulmonary fibrosis Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia Year: 2019